Skip to main content
Log in

Resektabilität des Pankreaskarzinoms

Neue Kriterien

Resectability of pancreatic cancer

New criteria

  • Leitthema
  • Published:
Der Radiologe Aims and scope Submit manuscript

Zusammenfassung

Hintergrund

Das Pankreaskarzinom hat nach wie vor eine sehr schlechte Prognose. Die chirurgische Resektion ist der einzige kurative Therapieansatz, womit heute zumindest für 25 % der Patienten ein 5‑Jahres-Überleben erreicht werden kann. In den letzten Jahren wurden zunehmend Fortschritte in der chirurgischen Technik gemacht, wodurch sich die Kriterien der Resektabilität wesentlich geändert haben. Diese sollen nachfolgend detailliert dargestellt werden.

Ziel der Arbeit

Darstellung aktueller Resektabilitätskriterien beim Pankreaskarzinom.

Material und Methoden

Selektive Literaturrecherche und Zusammenfassung der derzeitig gängigsten Kriterien zur Resektabilität beim Pankreaskarzinom.

Ergebnisse

Bei Patienten mit Pankreaskarzinom muss zwischen primär resektablen, Borderline-resektablen, lokal fortgeschrittenen (primär nicht resektablen) und metastasierten Befunden unterschieden werden. Während Tumorinfiltrationen von Gefäßen früher ein absolutes Ausschlusskriterium für eine Resektion darstellten, kann heute bei einer Tumorinfiltration benachbarter Venen (V. mesenterica superior, Pfortader und Konfluens/V. lienalis) eine chirurgische Resektion in aller Regel sicher vorgenommen werden. Ein persistierendes Problem stellen Tumorinfiltrationen in benachbarte arterielle Gefäße (A. hepatica, A. mesenterica superior und Truncus coeliacus) dar. Obwohl eine Resektion in diesen Fällen technisch häufig möglich wäre, ist diese aufgrund von erhöhter Morbidität und Mortalität der Eingriffe als auch eines schlechteren onkologischen Outcomes derzeit nur in Einzelfällen indiziert. Eine besondere Gruppe stellen die Borderline-resektablen Tumoren dar, bei denen zunehmend neoadjuvante Therapiekonzepte zur Anwendung kommen. Die Evaluation des Therapieansprechens stellt hier eine besondere Herausforderung dar, da dies in aller Regel nicht mit einer radiologisch nachweisbaren Reduktion des Tumorvolumens einhergeht.

Schlussfolgerungen

Aufgrund von Fortschritten in der chirurgischen Technik sind heute radikalere Pankreasoperationen sicher durchführbar, wodurch sich auch die Resektabilitätskriterien in den letzten Jahren insbesondere bzgl. venöser Tumorinfiltrationen deutlich verändert haben.

Abstract

Background

Pancreatic cancer is notoriously one of the most aggressive cancers and still has a poor prognosis. Surgical resection is the only chance for a curative therapy approach, with which at least a 5‑year survival can be achieved for 25 % of patients. Recent advances in surgical techniques have led to a change in the criteria for resectability.

Objective

This review summarizes the currently available evidence on the criteria for resectability of pancreatic cancer and discusses the treatment options.

Material and methods

The study was based on a selective literature search and a summary of the latest data on criteria for resectability is given.

Results

Patients with pancreatic cancer must be differentiated into those with primarily resectable disease, borderline resectable disease, locally advanced (primarily unresectable) and metastatic disease. While infiltration into the major surrounding venous vessels (e.g. superior mesenteric vein, portal vein and confluence of splenic vein) used to be a criterion for unresectable disease, these tumors can nowadays be safely resected in specialized centers. Tumor infiltration into adjacent arteries (e.g. hepatic artery, superior mesenteric artery and celiac artery) remains a clinical problem and surgical resection is often technically possible but associated with an increased morbidity and mortality and therefore not generally recommended. Borderline resectable tumors represent a special group for which neoadjuvant treatment concepts are increasingly being implemented. Radiological therapy response evaluation is challenging after neoadjuvant therapy as it is not usually associated with a radiologically detectable reduction in tumor volume.

Conclusion

Pancreatic resections can nowadays be more radically performed due to advances in surgical techniques. This has led to a change in the criteria for resectability, especially concerning venous tumor infiltration.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Abb. 1
Abb. 2
Abb. 3

Literatur

  1. Allema JH, Reinders ME, Van Gulik TM et al (1994) Portal vein resection in patients undergoing pancreatoduodenectomy for carcinoma of the pancreatic head. Br J Surg 81:1642–1646

    Article  CAS  PubMed  Google Scholar 

  2. Ammori JB, Colletti LM, Zalupski MM et al (2003) Surgical resection following radiation therapy with concurrent gemcitabine in patients with previously unresectable adenocarcinoma of the pancreas. J Gastrointest Surg 7:766–772

    Article  PubMed  Google Scholar 

  3. Bilimoria KY, Bentrem DJ, Ko CY et al (2007) National failure to operate on early stage pancreatic cancer. Ann Surg 246:173–180

    Article  PubMed  PubMed Central  Google Scholar 

  4. Birkmeyer JD, Siewers AE, Finlayson EV et al (2002) Hospital volume and surgical mortality in the United States. N Engl J Med 346:1128–1137

    Article  PubMed  Google Scholar 

  5. Birkmeyer JD, Sun Y, Wong SL et al (2007) Hospital volume and late survival after cancer surgery. Ann Surg 245:777–783

    Article  PubMed  PubMed Central  Google Scholar 

  6. Burdelski CM, Reeh M, Bogoevski D et al (2011) Multivisceral resections in pancreatic cancer: identification of risk factors. World J Surg 35:2756–2763

    Article  PubMed  Google Scholar 

  7. Butturini G, Stocken DD, Wente MN et al (2008) Influence of resection margins and treatment on survival in patients with pancreatic cancer: meta-analysis of randomized controlled trials. Arch Surg 143:75–83

    Article  PubMed  Google Scholar 

  8. Callery MP, Chang KJ, Fishman EK et al (2009) Pretreatment assessment of resectable and borderline resectable pancreatic cancer: expert consensus statement. Ann Surg Oncol 16:1727–1733

    Article  PubMed  Google Scholar 

  9. Chua TC, Saxena A (2010) Extended pancreaticoduodenectomy with vascular resection for pancreatic cancer: a systematic review. J Gastrointest Surg 14:1442–1452

    Article  PubMed  Google Scholar 

  10. Esposito I, Kleeff J, Bergmann F et al (2008) Most pancreatic cancer resections are R1 resections. Ann Surg Oncol 15:1651–1660

    Article  PubMed  Google Scholar 

  11. Ferrone CR, Marchegiani G, Hong TS et al (2015) Radiological and surgical implications of neoadjuvant treatment with FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer. Ann Surg 261:12–17

    Article  PubMed  PubMed Central  Google Scholar 

  12. Fuhrman GM, Leach SD, Staley CA et al (1996) Rationale for en bloc vein resection in the treatment of pancreatic adenocarcinoma adherent to the superior mesenteric-portal vein confluence. Pancreatic Tumor Study Group. Ann Surg 223:154–162

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Gillen S, Schuster T, Meyer Zum Buschenfelde C et al (2010) Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages. PLoS Med 7:e1000267

    Article  PubMed  PubMed Central  Google Scholar 

  14. Hackert T, Werner J, Weitz J et al (2010) Uncinate process first–a novel approach for pancreatic head resection. Langenbecks Arch Surg 395:1161–1164

    Article  PubMed  Google Scholar 

  15. Hartwig W, Hackert T, Hinz U et al (2011) Pancreatic cancer surgery in the new millennium: better prediction of outcome. Ann Surg 254:311–319

    Article  PubMed  Google Scholar 

  16. Hartwig W, Hackert T, Hinz U et al (2009) Multivisceral resection for pancreatic malignancies: risk-analysis and long-term outcome. Ann Surg 250:81–87

    Article  PubMed  Google Scholar 

  17. Hidalgo M (2010) Pancreatic cancer. N Engl J Med 362:1605–1617

    Article  CAS  PubMed  Google Scholar 

  18. Imamura M, Doi R, Imaizumi T et al (2004) A randomized multicenter trial comparing resection and radiochemotherapy for resectable locally invasive pancreatic cancer. Surgery 136:1003–1011

    Article  PubMed  Google Scholar 

  19. Katz MH, Pisters PW, Evans DB et al (2008) Borderline resectable pancreatic cancer: the importance of this emerging stage of disease. J Am Coll Surg 206:833–846; discussion 846–848

  20. Klauss M, Alt CD, Welzel T et al (2009) Multidetector CT evaluation of the course of nonresectable pancreatic carcinomas with neoadjuvant therapy. Pancreatology 9:621–630

    Article  CAS  PubMed  Google Scholar 

  21. Konstantinidis IT, Warshaw AL, Allen JN et al (2013) Pancreatic ductal adenocarcinoma: is there a survival difference for R1 resections versus locally advanced unresectable tumors? What is a „true“ R0 resection? Ann Surg 257:731–736

    Article  PubMed  Google Scholar 

  22. Mayo SC, Nathan H, Cameron JL et al (2012) Conditional survival in patients with pancreatic ductal adenocarcinoma resected with curative intent. Cancer 118:2674–2681

    Article  PubMed  PubMed Central  Google Scholar 

  23. Mollberg N, Rahbari NN, Koch M et al (2011) Arterial resection during pancreatectomy for pancreatic cancer: a systematic review and meta-analysis. Ann Surg 254:882–893

    Article  PubMed  Google Scholar 

  24. Morgan DE, Waggoner CN, Canon CL et al (2010) Resectability of pancreatic adenocarcinoma in patients with locally advanced disease downstaged by preoperative therapy: a challenge for MDCT. AJR. Am J Roentgenol 194:615–622

    Article  Google Scholar 

  25. Neoptolemos JP, Stocken DD, Bassi C et al (2010) Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. JAMA 304:1073–1081

    Article  CAS  PubMed  Google Scholar 

  26. Pessaux P, Rosso E, Panaro F et al (2009) Preliminary experience with the hanging maneuver for pancreaticoduodenectomy. Eur J Surg Oncol 35:1006–1010

    Article  CAS  PubMed  Google Scholar 

  27. Strobel O, Berens V, Hinz U et al (2012) Resection after neoadjuvant therapy for locally advanced, „unresectable“ pancreatic cancer. Surgery 152:S33–42

    Article  PubMed  Google Scholar 

  28. Varadhachary GR, Tamm EP, Abbruzzese JL et al (2006) Borderline resectable pancreatic cancer: definitions, management, and role of preoperative therapy. Ann Surg Oncol 13:1035–1046

    Article  PubMed  Google Scholar 

  29. Weitz J, Rahbari N, Koch M et al (2010) The „artery first“ approach for resection of pancreatic head cancer. J Am Coll Surg 210:e1–4

    Article  PubMed  Google Scholar 

  30. Werner J, Combs SE, Springfeld C et al (2013) Advanced-stage pancreatic cancer: therapy options. Nat Rev Clin Oncol 10:323–333

    Article  CAS  PubMed  Google Scholar 

  31. Zhou Y, Zhang Z, Liu Y et al (2012) Pancreatectomy combined with superior mesenteric vein-portal vein resection for pancreatic cancer: a meta-analysis. World J Surg 36:884–891

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to J. Werner.

Ethics declarations

Interessenkonflikt

J.G. D’Haese und J. Werner geben an, dass kein Interessenkonflikt besteht.

Dieser Beitrag beinhaltet keine von den Autoren durchgeführten Studien an Menschen oder Tieren.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

D’Haese, J.G., Werner, J. Resektabilität des Pankreaskarzinoms. Radiologe 56, 318–324 (2016). https://doi.org/10.1007/s00117-016-0092-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00117-016-0092-z

Schlüsselwörter

Keywords

Navigation